Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Johnson & Johnson acquires medical device company behind new LAA technology for $400M

The deal could also include additional clinical and regulatory milestone payments in the years ahead.

Cardiawave Valvosoft non-invasive ultrasound therapy

Cardiawave’s non-invasive ultrasound therapy impresses cardiologists early on—could it be an alternative to SAVR, TAVR?

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

Medtronic Penditure Left Atrial Appendage (LAA) Exclusion System

Medtronic debuts new FDA-cleared LAA exclusion device

Medtronic acquired the technology behind the new device back in August.

Smartphone app helps TAVR patients avoid major complications

Hospital readmissions, ER visits and major complications were all less likely when TAVR patients used a smartphone app to assist with their recovery. 

Prosthesis-patient mismatch (PPM) after TAVR

Cardiologists may want to rethink how they track prosthesis-patient mismatch after TAVR

Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice. 

Thumbnail

TAVR linked to favorable outcomes for asymptomatic and minimally symptomatic patients—but is it necessary?

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

Firas Zahr, MD,director of interventional cardiology, co-director, complex heart valve program, Oregon Health and Science University, discusses the one-year outcomes for transferral transcatheter mitral valve replacement (TMVR) in the Medtronic Intrepid Early Feasibility Study presented at TCT 2023.

Intrepid transfemoral transcatheter mitral valve shows favorable results after 1 year

Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.

TAVR utilization skyrocketed over 5-year period, improving survival for older AS patients

The study focused on patients 65 years old and older who underwent treatment in one of 21 high-income countries. 

Displaying 185 - 192 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup